Vcanbio Cell & Gene Engineering Corp Ltd Financials

Market Capitalization CN¥9.36 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	83.38
Forward PE	45.48
Price to Sales TTM	CN¥5.88
Price to Book MRQ	CN¥2.52
Enterprise to Revenue	4.93
Enterprise to EBITDA	32.51

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	6.74%
Operating Margin	14.65%
Return on Assets TTM	1.63%
Return on Equity TTM	2.71%

Income Statement

Revenue TTM	CN¥1,593,264,128
Revenue per Share TTM	CN¥3.52
Quarterly Revenue Growth	-0.20%
Gross Profit TTM	CN¥1,090,646,528
EBITDA	CN¥199,601,710
Net Income to Common TTM	CN¥107,453,816
Diluted EPS TTM	CN¥0.24
Quarterly Earnings Growth YoY	-3.00%

Balance Sheet

Total Cash MRQ	CN¥1,438,428,544
Total Cash per Share MRQ	CN¥3.16
Total Debt MRQ	CN¥
Total Debt to Equity MRQ	3.37
Current Ratio MRQ	1.66
Book Value per Share MRQ	CN¥7.93

Cash Flow

Operating Cash Flow TTM	CN¥290,753,376
Levered Free Cash Flow TTM	CN¥156,942,416

600645 Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	467,948,992
Float Shares	341,789,903
Avg 10 Volume	6,634,385
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	26.28%
% Held by Institutions	2.98%

Stock Price Summary

Beta	0.39
Fifty Two Week Low	CN¥12.88
Fifty Two Week High	CN¥24.08
Fifty Two Week Change	15.04%
Day 50 MA	CN¥20.08
Day 200 MA	CN¥18.42

Dividends and Splits

Forward Annual Dividend Rate	CN¥
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	CN¥0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2001-08-10
Last Split Factor
Last Split Date	2007-01-24